Theravance-GSK's COPD drug wins support of FDA panel

04/18/2013 | Reuters · Bloomberg Businessweek

A panel of FDA advisers endorsed the approval of GlaxoSmithKline and Theravance's Breo Ellipta as a treatment for chronic obstructive pulmonary disease. The once-daily inhaled treatment, a combination of fluticasone furoate and vilanterol, would compete with GSK's Advair and AstraZeneca's Symbicort. The FDA could issue a decision by May 12.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA